FY2028 Earnings Forecast for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at Leerink Partnrs cut their FY2028 EPS estimates for Elanco Animal Health in a research note issued to investors on Tuesday, October 14th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $1.33 per share for the year, down from their prior forecast of $1.34. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share.

A number of other equities analysts have also recently weighed in on ELAN. Piper Sandler increased their price target on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 11th. Zacks Research raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 3rd. William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Wall Street Zen upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Finally, Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.14.

Elanco Animal Health Price Performance

ELAN stock opened at $20.52 on Wednesday. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $21.76. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $10.19 billion, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 3.71 and a beta of 1.65. The business has a fifty day moving average of $18.72 and a two-hundred day moving average of $14.60.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the prior year, the company posted $0.30 EPS. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after buying an additional 2,090 shares during the period. First Horizon Advisors Inc. boosted its stake in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after buying an additional 2,414 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Elanco Animal Health by 261.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after buying an additional 2,922 shares in the last quarter. Finally, Wealthquest Corp purchased a new stake in shares of Elanco Animal Health during the first quarter worth approximately $56,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.